$Gyre Therapeutics (GYRE.US)$
The parent company's stock price is not looking good either.
Having long awaited the F351, waiting a bit longer is not a big deal, but I want to know what is going on with Jaiko's IR system 💧.
There is also doubt about the parent company announcing results before the child company. Furthermore, there is no visibility regarding the usual IR activities...
It's not just about merely disclosing that the top line was good; they need to mention other matters arising from the favorable results in the NASH phase 2 as a matter of course.

$Alt (260A.JP)$
It's going up, isn't it~
I'm glad I prepared it in advance.

$PeptiDream (4587.JP)$
Even if good materials come out, and the performance is not bad, why does it drop so much~(T_T)
Looking forward to next week's earnings announcement!
Hang in there, Pepchi‼️

$Futu Holdings Ltd (FUTU.US)$
The MOOMOO app is so easy to use that out of gratitude, a share will be bought. It was just opened this year, but it feels overwhelming compared to SBI, Rakuten, and Matsui.

$Gyre Therapeutics (GYRE.US)$
Follow Acera〜🚀

$Alt (260A.JP)$
After going public, the recent stock price has been lackluster (due to losses), but it is expected to turn profitable next fiscal year. There is growth potential in the personal AI sector. It may be a good idea to buy while it's cheap. With a small number of stocks, it may be difficult to buy once it starts to rise (possibility of frequent trading halts).

$Gyre Therapeutics (GYRE.US)$
I have the same Financial Estimates for the top line since the beginning of the year, and if it comes out within the year, I'll be excited 🍺.

$Gyre Therapeutics (GYRE.US)$  
This is a soliloquy about PULM.
When it comes to CBIO, those who bought at the timing of obtaining CVR rights, rather than jumping in during the initial rise (as it was dropping due to the approval gambling fatigue).
Needless to say, I am one of the individuals who jumped into CBIO 😂 So, crossing the approval, I enjoyed the delicious CVR 👍 It might be good either way for the mid to long term.
Certainly, I think I will buy PULM after understanding the details m(__)m.